Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas

Pathology Research and Practice

Volumn 196, Issue 7, 2000, Pages 469-475

  Mayr, Doris ^a   Pannekamp, Uwe ^a   Baretton, Gustavo Bruno ^a   Gropp, Martina ^a   Meier, Werner ^a   Flens, Marcel Jan ^b   Scheper, Rik ^b   Diebold, Joachim ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Drug resistance; Immunohistochemistry; Major vault protein; Ovarian carcinomas Glutathione S transferase; p53

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; GLUTATHIONE TRANSFERASE; LUNG RESISTANCE PROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MINIMAL RESIDUAL DISEASE; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; PROGNOSIS;

EID: 0033926677     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0344-0338(00)80048-5     Document Type: Article

References (26)

1. Advanced Ovarian Cancer Trialists Group (1991) Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Brit Med J 303: 884-892
2. Bishop JF, Macarounas-Kirchman K (1997) The pharmacoeconomics of cancer therapies. Seminars in Oncology 24: Suppl 16: S19-106-111
3. Christodoulou CV, Eliopoulos AG, Young LS, Hodgkins L, Ferry DR, Kerr DJ (1998) Anti-proliferative activity and mechanism of action of titanocene dichloride. Brit J Cancer 77: 2088-2097
4. Coukos G, Rubin SC (1998) Chemotherapy resistance in ovarian cancer: New molecular perspectives. Obstet Gynecol 91: 783-797
5. Diebold J, Baretton G, Felchner M, Meier W, Löhrs U (1997) bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 105: 341-349
6. Flens MJ (1997) Novel drug resistance-associated proteins. Academisch Proefschrift, Free University of Amsterdam
7. Hamada SI, Kamada M, Furumoto H, Hirao T, Aono T (1994) Expression of glutathione S-transferase-pi in human ovarian cancer as an indicator of resistance to chemotherapy. Gynecol Oncol 52: 313-319
8. Harstrick A, Schmoll HJ, Sass G, Poliwoda H, Rustum Y (1993) Activity of a novel metal compound, titanocene dichloride in cisplatin and doxorubicin resistant human ovarian carcinoma cell lines. Eur J Cancer 29: 1000-1002
9. Holford J, Sharp SY, Murrer BA, Abrams M, Kelland LR (1998) In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Brit J Cane 77: 366-373
10. Izquierdo MA, van der Zee AGJ, Vermorken JB et al (1996) Drug resistance-associated marker Lrp for predictation of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 87: 1230-1237
11. Kaye SB, Piccart M, Aapro M, Francis P, Kavanagh J (1997) Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer - an updated overview. Eur J Cancer 13: 2167-2170
12. Kedersha NL, Rome LH (1986) Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA. J Cell Biol 103: 699-709
13. Kelland LR (1993) New platinum antitumor complexes. Crit Rev Oncol Hemat 15: 191-219
14. Kigawa J, Minagawa Y, Kanamori Y et al (1998) Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer. Cancer 15: 697-702
15. Koshiyama M, Konishi I, Mandai M, Komatsu T, Yamamoto S, Nanbu K, Mori T (1995) Immunohistochemical analysis of p53 protein and 72 kDa heat shock protein (HSP72) expression in ovarian carcinomas. Virchows Arch 425: 603-609
16. Krishan A, Morgan Fitz C, Andritsch I (1997) Drug retention, efflux, and resistance in tumor cells. Cytometry 29: 279-285
17. Kupryjanczyk J, Thor AD, Beachkamp R, Merritt V, Edgerton SM, Bell DA, Yandell DW (1993) p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci 90: 4961-4965
18. Lane DP (1992) p53, guardian of the genome. Nature 358: 15-16
19. McGuire WP, Hoskins WJ, Brady MF et al. (1996) Cyclophophamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl J Med 334: 1-6
20. Roland PY, Barnes MN, NIwas S et al (1998) Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimes. Gynecol Oncol 68: 178-182
21. Sarhanis P, Redman C, Perrett C et al (1996) Epithelial ovarian cancer: influence of polymorphism at the glutathione S-transferase GSTM1 and GSTT1 loci on p53 expression. Brit J Cancer 74: 1757-1761
22. Scheffer GL, Wijngaard PLJ, Flens MJ et al (1995) The drug resistance-related protein LRP is the human mayor vault protein. Nat Med 1: 578-582
23. Schroeijers B, Scheffer GL, Flens MJ et al (1998) Immunohistochemical detection of the human major vault protein LRP with two monoclonal antibodies in formalin-fixed, paraffin-embedded tissues. Am J Path 152: 373-378
24. Silvestrini R, Daidone MG, Veneroni S et al (1998) The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. Cancer 82: 159-167
25. Sobin LH, Wittekind Ch (Eds) International Union against Cancer, TNM classification of malignant tumours (1997). pp 152-156. Wiley-Liss, 5th ed., New York-Chichester-Weinheim
26. Zaffaroni N, Silvestrini R, Orlanis L, Bearzatto A, Gornati D, Villa R (1998) Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cis-platin-sensitivie and -resistant human ovarian cancel-cells. Brit J Cancer 77: 1378-1385